secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001654954-24-010104
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata Therapeutics reports Q2 2024 results; DMT310 Phase 3 trial enrollment over 50%
--------------------------------------------------------------------------------

- Net cash $4.9M at June 30, 2024, down from $7.4M at Dec 31, 2023; expects to fund ops into Q4 2024.
- Raised $2.3M in net proceeds from May 2024 warrant inducement financing.
- R&D expenses $2.0M in Q2 2024 vs. $0.8M in Q2 2023 due to STAR-1 trial costs.
- DMT310 Phase 3 STAR-1 trial enrolled over 50% of patients; topline data expected Q1 2025.
- DMT410 partnership discussions ongoing for topical botulinum toxin delivery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424010104/0001654954-24-010104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495424010104/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-010104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer